Meroterpenoid compounds for use in the prevention and treatment of a neurological disorder

Abstract

The present invention relates to a compound, in particular a meroterpenoid compound, or salt thereof, for use in the prevention and/or treatment of a neurological disorder in an individual. The compound of the invention can promote lactate secretion. A composition comprising the compound of the invention, and a food or food extract enriched with said compound or composition is also provided.

1 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (Ia) 
       
         
           
           
               
               
           
         
         wherein R1=H or a halogen; 
         R2=an isoprenoid chain or a modified isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and 
         R3=H or OH 
         or a salt thereof. 
       
     
     
         2 . A method according to  claim 1 , wherein the compound has the structural formula 
       
         
           
           
               
               
           
         
         wherein R1=H or a halogen; 
         R2=an isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and 
         R3=H or OH. 
       
     
     
         3 . A method according to  claim 1 , wherein the compound has a structural formula selected from the group consisting of:
 a. Structural formula (Ib)   
       
         
           
           
               
               
           
         
         wherein R1=H or a halogen; 
         R2=a cyclized isoprenoid chain or a modified cyclized isoprenoid chain and optionally further esterification comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and 
         R3=H or OH; 
         b. Structural formula (Ic) 
       
       
         
           
           
               
               
           
         
         wherein R1=H or a halogen; 
         R2=a cyclized isoprenoid chain with further hydroxylated side chain structure or a modified cyclized isoprenoid chain structure with further hydroxylated side chain structure comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and 
         R3=H or OH; and 
         c. Structural formula (Id); 
       
       
         
           
           
               
               
           
         
         wherein R1=H or a halogen; 
         R2=an open isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; and 
         R3=H or OH. 
       
     
     
         4 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (II) 
       
         
           
           
               
               
           
         
         wherein R1=phenethyl or a modified phenethyl side chain, and/or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; 
         R2=H or an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen; 
         R3=H or methyl, and 
         R4=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to 19 carbon atoms, hydrogen, and optionally oxygen 
         or a salt thereof. 
       
     
     
         5 . A method for prevention and/or treatment of a neurological disorder in an individual, the method comprising administering to the individual a compound of structural formula (III) 
       
         
           
           
               
               
           
         
         wherein R1=an isoprenoid chain or a modified open isoprenoid chain comprising 1 to carbon atoms, hydrogen, and optionally oxygen 
         R2=H or OH 
         or a salt thereof. 
       
     
     
         6 . A method according to  claim 3 , wherein the compound has structural formula (Ib). 
     
     
         7 . A method according to  claim 6 , wherein R1=Cl, and R3=H. 
     
     
         8 . A method according to  claim 6 , wherein the compound is ascochlorin. 
     
     
         9 . A method according to  claim 6 , wherein the compound is CAS 22562-67-0 (Illicicolin C). 
     
     
         10 . A method according to  claim 6 , wherein the compound is CAS 22738-98-3 (Illicicolin F). 
     
     
         11 . A method according to  claim 1 , wherein lactate secretion is promoted. 
     
     
         12 . A method according to  claim 1 , wherein the lactate secretion from astrocytes is promoted. 
     
     
         13 - 22 . (canceled)